Data Collection and Identification of Infection-responsible Bacterial Resistances in Cirrhotic Patients
NCT03965260 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 71
Last updated 2022-03-21
Summary
Cirrhotic patients have a high risk of bacterial infection. These infections induce systemic inflammation that can lead to acute liver failure or even acute liver failure associated with multi-visceral failure (Acute-to-Chronic Liver Failure, ACLF) associated with an increased risk of short-term mortality in this population.
The most common infections are spontaneous bacterial peritonitis and urinary tract infections, followed by pneumonia, skin and soft tissue infections and spontaneous bacteremia.
In order to cope with the growing risk of resistant bacterial infections, recommendations from the European Association for the Study of the Liver (EASL) were issued in 2014 and are followed by physicians treating cirrhotic patients. These recommendations advocate taking into account different parameters regarding the best therapeutic strategy to adopt. The site of the infection, the mode of acquisition or the presence or absence of prophylaxis may modify this therapeutic approach to infections of cirrhotic patients to a greater or lesser extent. However, the ecology of a center varies over time, according to the practices of the hospital center and to the different patients in care. It is recommended to update the antibiotic resistance data in order to propose the best therapeutic strategy for these patients.
The study of bacterial resistance in a given care center makes it possible to adapt the recommendations published by EASL in 2014 to the local ecology and to set up protocols of probabilistic antibiotic therapy adapted for a better efficiency.
This descriptive cohort study will determine the local ecology of the center. This will enable the center to assess if the recommended antibacterial strategies correspond to the center bacterial ecology.
Conditions
- Cirrhosis
Interventions
- BIOLOGICAL
-
Bacterial samples from blood or peritoneal liquids
For each cirrhotic patient hospitalized for a bacterial infection, a blood sample or a peritoneal liquid sample was collected and analyzed for susceptibility, as it is performed in the standard of care. Our department receives only the bacterial results. We will then describe the bacterial ecology of the center cirrhotic population in terms of infection acquisition mode, infection site, infection etiology but also drug-resistance.
Sponsors & Collaborators
-
Hospices Civils de Lyon
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-11-01
- Primary Completion
- 2020-01-31
- Completion
- 2020-03-31
Countries
- France
Study Locations
More Related Trials
-
Liver Cirrhosis Network Cohort Study
NCT05740358 ·Status: ACTIVE_NOT_RECRUITING
-
Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
NCT05669677 ·Status: COMPLETED
-
Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors
NCT07238114 ·Status: ACTIVE_NOT_RECRUITING
-
Study of Clinical Features of Patients With Autoimmune Liver Disease Complicated With Covid-19 and the Immune Mechanism Affecting Prognosis
NCT06099626 ·Status: UNKNOWN
-
Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies) and HCV Triple Therapy
NCT02877199 ·Status: COMPLETED
-
Identification and Verification of Neutrophil Extracellular Trap Net Related Markers in Acute-on-chronic Liver Failure
NCT05909319 ·Status: UNKNOWN
-
Assessment of the Predictive Value of Fecal Calprotectin for the Outcome of Severe Alcoholic Hepatitis
NCT02808663 ·Status: COMPLETED ·Phase: NA
-
Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis
NCT03693586 ·Status: COMPLETED
-
French National MICMAF Cohort
NCT05895890 ·Status: RECRUITING
-
Metabolic Associated Fatty Liver Disease in Patients With Chronic Glomerular Disease
NCT06691529 ·Status: NOT_YET_RECRUITING
-
Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)
NCT02038387 ·Status: UNKNOWN ·Phase: NA
-
Cytokines and the Risk of Infection in Liver Cirrhosis
NCT00857181 ·Status: TERMINATED
-
S100A8/A9 and Innate Immunity in Liver Disease
NCT05793983 ·Status: UNKNOWN
-
Bartonella in Liver Transplant Patients
NCT02595710 ·Status: COMPLETED
-
Cell Bound Complement Activation Proteins as Markers of Liver Injury
NCT01025531 ·Status: WITHDRAWN
-
UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease
NCT05812612 ·Status: UNKNOWN
-
Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations
NCT01517529 ·Status: COMPLETED
-
Study of the Role of Dendritic Cells in the Recurrence of Hepatitis C After Liver Transplantation. Analysis of Hepatitis C Virus (HCV) Quasispecies Evolution.
NCT00213707 ·Status: UNKNOWN
-
Gene Expression in Liver Allograft Rejection and Recurrent Hepatitis C
NCT01428700 ·Status: COMPLETED
-
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis
NCT00160940 ·Status: UNKNOWN
-
Lyon Granulomatous Hepatitis Study
NCT04459897 ·Status: UNKNOWN
-
COVID-19 and Nonalcoholic Fatty Liver Disease
NCT04982328 ·Status: COMPLETED
-
Predictors of Spontaneous Bacterial Peritonitis Among Patients with Cirrhosis
NCT06884306 ·Status: NOT_YET_RECRUITING
-
The Role of Immune Semaphorins in NAFLD
NCT04573543 ·Status: COMPLETED
-
Single Cell Landscape of HBV-related Acute-on-chronic Liver Failure Patients
NCT06865859 ·Status: RECRUITING